Department of Cardiology, Odense University Hospital, Denmark (T.M.H., S.K.N., J.E.M., J.M.).
Odense Patient Data Explorative Network (OPEN), Odense University Hospital, Denmark (T.M.H., .K.N., J.E.M., J.M.).
Circ Heart Fail. 2020 Oct;13(10):e006701. doi: 10.1161/CIRCHEARTFAILURE.119.006701. Epub 2020 Oct 6.
It was the aim to investigate the frequency and genetic basis of dilated cardiomyopathy (DCM) among relatives of index patients with unexplained heart failure at a tertiary referral center.
Clinical investigations were performed in 109 DCM index patients and 445 of their relatives. All index patients underwent genetic investigations of 76 disease-associated DCM genes. A family history of DCM occurred in 11% (n=12) while clinical investigations identified familial DCM in a total of 32% (n=35). One-fifth of all relatives (n=95) had DCM of whom 60% (n=57) had symptoms of heart failure at diagnosis, whereas 40% (n=38) were asymptomatic. Symptomatic relatives had a shorter event-free survival than asymptomatic DCM relatives (<0.001).
Genetic investigations identified 43 pathogenic (n=27) or likely pathogenic (n=16) variants according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology criteria. Forty-four percent (n=48/109) of index patients carried a pathogenic/likely pathogenic variant of whom 36% (n=27/74) had sporadic DCM, whereas 60% (21/35) were familial cases. Thirteen of the pathogenic/likely pathogenic variants were also present in ≥7 affected individuals and thereby considered to be of sufficient high confidence for use in predictive genetic testing.
A family history of DCM identified only 34% (n=12/35) of hereditary DCM, whereas systematic clinical screening identified the remaining 66% (n=23) of DCM families. This emphasized the importance of clinical investigations to identify familial DCM. The high number of pathogenic/likely pathogenic variants identified in familial DCM provides a firm basis for offering genetic investigations in affected families. This should also be considered in sporadic cases since adequate family evaluation may not always be possible and the results of the genetic investigations may carry prognostic information with an impact on individual management.
本研究旨在调查一家三级转诊中心中,不明原因心力衰竭患者的亲属中扩张型心肌病(DCM)的频率和遗传基础。
对 109 名 DCM 指数患者和 445 名亲属进行临床调查。所有指数患者均接受了 76 种与疾病相关的 DCM 基因的遗传调查。11%(n=12)的指数患者有 DCM 家族史,而总的来说,32%(n=35)的临床调查确定了家族性 DCM。所有亲属中有五分之一(n=95)患有 DCM,其中 60%(n=57)在诊断时就有心力衰竭症状,而 40%(n=38)无症状。有症状的亲属无事件生存率低于无症状 DCM 亲属(<0.001)。
根据美国医学遗传学与基因组学学院和分子病理学协会的标准,遗传调查确定了 43 种致病性(n=27)或可能致病性(n=16)变异。44%(n=109)的指数患者携带致病性/可能致病性变异,其中 36%(n=27/74)为散发性 DCM,而 60%(n=35)为家族性病例。13 种致病性/可能致病性变异也存在于≥7 名受影响的个体中,因此被认为具有足够的高可信度,可用于预测性基因检测。
DCM 家族史仅确定了 34%(n=35)的遗传性 DCM(n=12),而系统的临床筛查确定了其余 66%(n=23)的 DCM 家族。这强调了进行临床调查以确定家族性 DCM 的重要性。在家族性 DCM 中确定的致病性/可能致病性变异数量较多,为对受影响的家族进行遗传调查提供了坚实的基础。这也应在散发性病例中考虑,因为并非总能进行充分的家族评估,而且遗传调查的结果可能具有预后信息,对个体管理产生影响。